Ramipril capsules move along the production line at the Lupin Ltd. pharmaceutical plant in Salcette, Goa, India, on Friday, Feb. 7, 2014. Lupin, founded by billionaire Desh Bandhu Gupta, expects to gain share in the U.S. amid increased regulatory oversight and curbs on competitors including Ranbaxy Laboratories Ltd. Photographer: Dhiraj Singh/BloombergAI Quick ReadPharma major Lupin’s shares are likely to be on investors’ radar during Thursday's session, April 9, as the company announced the approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States.
The company, in its regulatory filing on Wednesday, said it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in strengths of 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg.
The USFDA-approved product is bioequivalent to Xigduo XR and will be used for the same indications as per the approved label.
Earlier this month, the company announced the completion of its acquisition of VISUfarma B.V., a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO).
The acquisition marks the company’s ongoing strategy to expand its specialty care portfolio and strengthen its presence in Europe.
The company further said that VISUfarma enhances its ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the rising burden of diabetes-related eye complications.
Founded in 2016 through the combination of the Italian company Visufarma SpA and the European commercial activities of Nicox SA, VISUfarma is a specialty pharmaceutical company focused on ophthalmology. It generated €53 million in revenue in 2025 across Italy, the UK, Spain, Germany, France, and certain international markets, according to the company’s regulatory filing dated April 1.
The company’s shares have been maintaining a winning streak, ending each of the last six months in the green, resulting in a 22% gain. The stock had earlier witnessed a similar bull run between April 2023 and August 2024, during which it gained 263%.
In terms of yearly performance, the stock delivered a negative return of 10.45% in 2025 after delivering positive returns in the preceding two consecutive years.
Disclaimer: We advise investors to check with certified experts before making any investment decisions.
Ksheera Sagar has been working as a Market Research Analyst at LiveMint for the past four years, covering stocks, commodities, and broader financial markets. In this role, he closely tracks daily market movements, corporate earnings, sector trends, and macroeconomic developments.
<br><br>
He has over a decade of experience in the financial services industry and has previously worked with multiple organisations, including global investment bank J.P. Morgan, bringing strong research experience into the newsroom.
<br><br>
During his career, he has gained extensive exposure to equity research, market analysis, and financial data interpretation, strengthening his expertise across asset classes and market cycles.
<br><br>
He is known for his data-driven analysis and crisp, listicle-style market stories that break down complex financial developments across key markets for a wide audience. His strong research skills enable him to write detailed and insightful stories on stocks and sectors, focusing on the underlying factors driving market movements.
<br><br>
His work combines quantitative insights with clear storytelling, presenting financial developments in a clear and structured manner. Moreover, he enjoys writing multibagger and listicle-style copies. Outside of work, Ksheera enjoys playing the piano and exploring new places. He has a keen interest in travel, music, and continuously learning about global markets and economic trends.